Journal Article 4 Mentions
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Gill Livingston•2024
Jonathan D. HuntleyKathy Y Liu
Top 1% · 100th Percentile
3,830 citations · Psychiatry and Mental health
Open Access

TLDR

Many dementia cases could potentially be delayed by improving health and living conditions throughout life. People who already have dementia can also benefit from personalised care, support for families, and some medicines, although newer treatments have limited benefits and serious costs.

Summary

1 Study Aim

The Lancet Commission aimed to update evidence on dementia prevention, diagnosis, treatment, and care since its 2020 report. The authors sought to identify additional changeable risks, estimate their combined prevention potential, and recommend policies and clinical practices. They also examined newer blood tests, medicines, and support for people with dementia and their families. Dementia risk can be reduced through lifelong action, while better care can improve daily life after diagnosis.

2 Study Design

An international, interdisciplinary expert group used a triangulation framework, comparing systematic reviews, meta-analyses, trials, observational studies, and causal-inference research. The commission conducted new meta-analyses of hearing loss and depression. It updated worldwide risk estimates and prevalence data for 14 factors. Researchers used 37,000 participants from Norway’s HUNT study to measure overlap among risks. They then calculated the population attributable fraction (PAF), meaning the share of cases linked to these risks. The report also reviewed diagnostic tools, biomarkers, drug trials, psychosocial interventions, and dementia care evidence across different countries. The researchers combined many existing studies with new analyses to update recommendations for prevention and care.

3 Findings

The authors identify 14 potentially changeable risks: limited education, hearing loss, high blood pressure, smoking, obesity, depression, inactivity, diabetes, excess alcohol, head injury, air pollution, social isolation, vision impairment, and high LDL cholesterol (low-density lipoprotein cholesterol). Together, these risks account for an estimated 45.3% of dementia cases, although this does not guarantee prevention for any individual. Benefits may occur at any age and across genetic-risk groups. Hearing aids, depression treatment, smoking cessation, blood-pressure control, exercise, and air-quality improvements show supportive evidence. Personalised multidomain programs produce small cognitive benefits, while evidence for preventing dementia remains uncertain. Cholinesterase inhibitors (medicines that support brain chemical signalling) offer modest benefits. Anti-amyloid antibodies slow decline slightly but require costly monitoring and can cause serious side effects. Blood biomarkers are not yet suitable for population prediction. The commission recommends equitable prevention policies, timely diagnosis without population screening, culturally adapted care, carer support, and person-centred activities. Improving health and social conditions early and throughout life offers the strongest practical opportunity to delay dementia and support families.

Referenced In